IQVIA Holdings Inc. (IQV) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services...
IQVIA Holdings Inc. (IQV) currently trades at a P/E ratio of 32.09 (historical range: 18.22–33.04, median: 25.86), placing it at the 96th percentile — expensive relative to its history, P/S ratio of 2.67 (range: 1.57–3.06, 92th percentile — expensive relative to its history), EV/EBITDA of 109.59 (range: 18.26–110.42, 100th percentile).
IQVIA Holdings Inc. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 32.09 | 18.22 | 25.86 | 33.04 | 96th | expensive relative to its history |
| P/S Ratio | 2.67 | 1.57 | 2.20 | 3.06 | 92th | expensive relative to its history |
| EV/EBITDA | 109.59 | 18.26 | 39.55 | 110.42 | 100th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.03 | 0.07 | 0th | expensive relative to its history |